Moreover, in these cells, we have investigated whether the inhibition of the deubiquitinase USP7, by lowering the CCDC6 levels and impairing the homologous recombination (HR) processes may increase the prostate cancer cells sensitivity to PARP inhibitors. This evidence concerns the gene CCDC6 and prostate carcinoma.